



THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER VAGINAL DELIVERY

1. Aim

This guideline summarises the available evidence on the prevention of venous thromboembolism (VTE) during pregnancy and following vaginal delivery. It does not address thromboprophylaxis following caesarean section¹ or the acute management of VTE in pregnancy, which was the subject of a previous guideline.²

2. Introduction and background

Pulmonary thromboembolism (PTE) is the most common direct cause of maternal death in the UK.³ Successive reports on Confidential Enquiries into Maternal Deaths have highlighted failures in recognising risk factors for VTE and employing adequate prophylaxis. Although PTE remains the leading cause of maternal death, in the latest Confidential Enquiry,³ the proportion of postpartum deaths following caesarean section had fallen, suggesting that adoption of published recommendations¹ may have had a beneficial effect. However, no impact has been made over the last decade on reducing the four to five deaths annually from antenatal PTE or the three deaths annually from PTE following vaginal delivery.³ In the most recent Confidential Enquiries into Maternal Deaths, 8/13 (62%) of women with fatal antenatal PTE died in the first trimester and 10/14 (71%) of postpartum deaths followed vaginal delivery.³ Although most VTE occurs antenatally, the risk per day is greatest in the weeks immediately after delivery.⁴ All women dying from VTE following vaginal delivery in the last Confidential Enquiry were either overweight or over the age of 35 years.³ Only one of the ten deaths involved operative vaginal delivery.³ This enquiry concluded that 'there is a clear need for the development of national guidelines on thromboprophylaxis after normal delivery'.³

3. Identification and assessment of evidence

A search of Medline from 1966 to 2002 was performed to identify all relevant randomised controlled trials (RCTs), systematic reviews and meta-analyses. The databases were searched using the relevant MeSH terms including all subheadings. The principal terms used were: 'venous thromboembolism', 'thrombosis', 'pregnancy', 'postpartum', 'puerperium', 'antenatal' and 'prenatal'.

In addition, current guidelines for the prevention of VTE in pregnancy and the puerperium were reviewed.⁵⁻⁷ A Cochrane review has highlighted the lack of evidence from randomised trials evaluating strategies for the prevention of VTE during pregnancy⁸ and, in general, guideline recommendations for the prevention of VTE during pregnancy are extrapolated from studies in nonpregnant women.

The definitions of types of evidence used in this guideline originate from the US Agency for Health Care Research and Quality. Where possible, recommendations are based on, and explicitly linked to, the evidence

that supports them. Areas lacking evidence are highlighted and annotated as ‘good practice points’.

4. Preconception antenatal risk assessment

4.1 Risk factors

Pregnancy is a risk factor for VTE and is associated with a ten-fold increase compared with the risk for nonpregnant women. Some women are at even higher risk during pregnancy because they have one or more additional risk factors (Table 1).^{9,10} The level of risk associated with many of these factors is unclear, however. An individual assessment of thrombotic risk should be undertaken, ideally before pregnancy or in early pregnancy. Women at high risk of VTE, including those with previous confirmed VTE, should be offered pre-pregnancy counselling with a prospective management plan. This is important because thrombotic risk exists from the beginning of the first trimester and often the antenatal booking visit is at the end of the first trimester.

All women should undergo an assessment of risk factors for VTE in early pregnancy or before pregnancy. This assessment should be repeated if the woman is admitted to hospital or develops other intercurrent problems.

C

| Table 1. Risk factors for venous thromboembolism in pregnancy and the puerperium ^a | |
|---|---|
| Pre-existing | New onset or transient ^b |
| Previous VTE | Surgical procedure in pregnancy or puerperium, e.g. evacuation of retained products of conception, postpartum sterilisation |
| Thrombophilia congenital | Hyperemesis |
| antithrombin deficiency | Dehydration |
| protein C deficiency | Ovarian hyperstimulation syndrome |
| protein S deficiency | Severe infection, e.g. pyelonephritis |
| Factor V Leiden | Immobility (> 4 days bed rest) |
| prothrombin gene variant | Pre-eclampsia |
| acquired (antiphospholipid syndrome) | Excessive blood loss |
| lupus anticoagulant | Long-haul travel |
| anticardiolipin antibodies | Prolonged labour ^c |
| Age over 35 years | Midcavity instrumental delivery ^c |
| Obesity (BMI > 30 kg/m ²) either pre-pregnancy or in early pregnancy | Immobility after delivery ^c |
| Parity > 4 | |
| Gross varicose veins | |
| Paraplegia | |
| Sickle cell disease | |
| Inflammatory disorders e.g. inflammatory bowel disease | |
| Some medical disorders, e.g. nephrotic syndrome, certain cardiac diseases | |
| Myeloproliferative disorders, e.g. essential thrombocythaemia, polycythaemia vera | |

^a Although these are all accepted as thromboembolic risk factors, there are few data to support the degree of increased risk associated with many of them; ^b these risk factors are potentially reversible and may develop at later stages in gestation than the initial risk assessment or may resolve; an ongoing individual risk assessment is important; ^c risk factors specific to postpartum VTE only

4.2 Investigation of women with previous VTE

Women with previous VTE have an increased risk of recurrence in pregnancy.¹¹ A retrospective comparison of the overall risk of recurrence of VTE during pregnancy and the nonpregnant period revealed risks of 10.9% during and 3.7% outside pregnancy. Using regression analysis gave a relative risk during pregnancy of 3.5 (95% CI 1.6–7.8).¹¹

Evidence level III

For women with a single previous thrombosis and no known thrombophilia, the risk of recurrence in pregnancy was increased to 2.0–3.0%¹² from about 0.1%.¹³ However, the risk was higher if the woman had thrombophilia or if the previous VTE was in an unusual site or was unprovoked.¹¹

Evidence
level III

Women with a previous VTE should have a careful history documented and undergo screening for both inherited and acquired thrombophilia, ideally before pregnancy. The relevant inherited and acquired thrombophilias are listed in Table 1. It is important to be aware of the effects of pregnancy on the results of a thrombophilia screen.² The diagnosis of a past VTE can be assumed if the woman gives a good history and received prolonged (6–12 weeks) therapeutic anticoagulation.

Women with previous VTE should be screened for inherited and acquired thrombophilia ideally before pregnancy.

B

5. Thromboprophylaxis during pregnancy and the puerperium

Expert haematological advice or referral to a joint obstetric and haematology clinic should be sought in cases when the antenatal team are uncertain about thromboprophylaxis.

Regardless of their risk of VTE, immobilisation of women during pregnancy, labour and the puerperium should be minimised and dehydration should be avoided.



5.1 Women with a previous VTE and no thrombophilia

Women with previous VTE and no thrombophilia should be offered prophylaxis with low molecular weight heparin (LMWH) for six weeks after delivery. Whether they also require antenatal thromboprophylaxis is controversial. There is some evidence that if the previous VTE was associated with a temporary risk factor, such as trauma, antenatal anticoagulation is not required.¹² Although pregnancy may be associated with a more than three-fold increase in the risk of recurrent VTE,¹¹ the evidence is conflicting. In a study of 125 pregnant women with a single previous VTE, none of the 44 women without thrombophilia whose previous VTE occurred in association with a temporary risk factor had a recurrence.¹² Of the 51 women with unprovoked first VTE or a thrombophilia, three³ (6%) had an antepartum recurrence, although the numbers were small and the analysis *post hoc*.¹² In addition, if the previous VTE was oestrogen-related (pregnancy or the combined oral contraceptive pill) or if there are additional risk factors such as obesity,⁵ thromboprophylaxis with LMWH has been advocated.

Women with previous VTE should be offered postpartum thromboprophylaxis with LMWH. It may be reasonable not to use antenatal thromboprophylaxis with heparin in women with a single previous VTE associated with a temporary risk factor that has now resolved.

C

Women who have had more than one previous episode of VTE, who have had one episode and in addition have a family history of VTE in a first degree relative or whose episode of VTE was in an unusual site (such as the axillary vein), all of which are markers for a thrombophilic state, should be considered for antenatal thromboprophylaxis with LMWH.^{6,7}

Women with previous recurrent VTE or a previous VTE and a family history of VTE in a first-degree relative should be offered thromboprophylaxis with LMWH antenatally and for at least six weeks postpartum.

C

5.2 Women with a previous VTE who have inherited thrombophilia

Women with thrombophilias have an increased risk of VTE in pregnancy^{12–14} but this risk varies depending

upon the specific thrombophilia.¹³ For example, in a case-control study, the relative risk for VTE was 7.0 for factor V Leiden, 9.5 for prothrombin G20210A, 10.0 for antithrombin deficiency and 107 for the combination of factor V Leiden and prothrombin.¹³ The relative risk of VTE due to the prothrombin mutation as outlined in this study¹³ is high compared with nonpregnant data and to a more recent case-control study.¹⁵ In this study of 119 consecutive women with a first VTE in pregnancy, the relative risks were 9.1 for factor V Leiden, 2.9 for prothrombin G20210A and 13.1 for deficiencies of antithrombin, protein C or S.¹⁵ The risk also depends on whether the woman or her close family have had a previous VTE.¹⁶⁻¹⁸ Current evidence supports, and existing guidelines recommend, that women with previous VTE and an identifiable thrombophilia should receive antenatal thromboprophylaxis with LMWH; prophylaxis should continue for six weeks postpartum.^{5-7,12-17}

Expert haematological advice should be sought for women with symptomatic thrombophilia, as specific thrombophilias, particularly AT deficiency, merit higher doses of LMWH (see Table 2) for thromboprophylaxis.

Women with previous VTE and thrombophilia should be offered thromboprophylaxis with LMWH antenatally and for at least six weeks postpartum.

B

| Prophylaxis | Enoxaparin (100 units/mg) | Dalteparin | Tinzaparin ^b |
|-------------------------------|---------------------------|----------------------|-------------------------|
| Normal body weight (50–90 kg) | 40 mg daily | 5000 units daily | 4500 units daily |
| Body weight < 50 kg | 20 mg daily | 2500 units daily | 3500 units daily |
| Body weight > 90 kga | 40 mg 12-hourly | 5000 units 12-hourly | 4500 units 12-hourly |
| Higher prophylactic dose | 40 mg 12-hourly | 5000 units 12-hourly | 4500 units 12-hourly |
| Therapeutic dose | 1 mg/kg 12-hourly | 90units/kg 12-hourly | 90units/kg 12-hourly |

^a Body mass index > 30 in early pregnancy
^b The dosage schedules for tinzaparin differ from the manufacturer's recommendation of once-daily dosage

5.3 Women with inherited thrombophilia without previous VTE

Increasingly, women present in pregnancy with a known thrombophilia, usually detected because of screening following identification of inherited thrombophilia in a family member. The risk of VTE associated with thrombophilia varies considerably.^{14,17} Antithrombin deficiency is associated with a high risk (30%)¹⁸ of VTE in pregnancy.¹⁹ Asymptomatic women with protein C or protein S deficiencies have an eight-fold increased risk of VTE associated with pregnancy but most events occur postpartum.²⁰ Data from retrospective family studies^{21,22} confirm a high risk of VTE for women with homozygous factor V Leiden (prevalence 15.8%²¹ to 17.0%;²² relative risk 41.3²¹) and combined defects of factor V Leiden and prothrombin gene mutation (prevalence 4.0%; relative risk 9.2²¹). Women heterozygous for the factor V Leiden mutation or the prothrombin gene variant are at considerably lower risk.¹³ Data from a case-control study would suggest an estimated risk of VTE in pregnancy of 1.2 in 100 for heterozygous factor V Leiden and one in 500 for heterozygous prothrombin G20210A. Prospective data examining the incidence of VTE in pregnant women with thrombophilia and no prior VTE are lacking.

Women should be stratified according to the level of risk associated with their thrombophilia. Since the risk of VTE is lower in women with no history of VTE, antenatal thromboprophylaxis is not always necessary, except in those with combined defects, those homozygous for defects or those with antithrombin deficiency.^{13,16,21-23} Women with antithrombin deficiency should always receive thromboprophylaxis in pregnancy and the puerperium.¹⁸

Women with known inherited or acquired thrombophilia may qualify for LMWH or warfarin for six weeks following delivery, even if they were not receiving antenatal thromboprophylaxis if they have other risk factors (see Table 1).

Women with asymptomatic inherited or acquired thrombophilia may qualify for antenatal or postnatal thromboprophylaxis, depending on the specific thrombophilia and the presence of other risk factors.

C

5.4 Women with acquired thrombophilia (antiphospholipid syndrome)

Antiphospholipid syndrome (APS) is defined as the presence of lupus anticoagulant or anticardiolipin antibodies of medium-high titre on two occasions eight weeks apart, found in association with a history of thrombosis (arterial or venous) or adverse pregnancy outcome (three or more unexplained miscarriages before ten weeks of gestation, a fetal death after ten weeks of gestation or a premature {less than 35 weeks} birth due to severe pre-eclampsia or intrauterine growth restriction).²⁴

The risk of recurrent thromboses in women with APS is up to 70%²⁵ and may be even higher in pregnancy. Therefore, pregnant women with APS and previous thromboses should receive antenatal and postnatal thromboprophylaxis with LMWH.²⁶

The management of women with obstetric manifestations of APS is more controversial. Low-dose aspirin has been shown to improve pregnancy outcome in APS and is recommended for all women with APS.²⁶ However, the presence of antiphospholipid antibodies with no previous 'APS classifiable' pregnancy loss²⁴ or thrombosis does not equate to APS²⁷ and such women do not require LMWH (or low-dose aspirin).^{28,29}

Women with antiphospholipid syndrome identified because of recurrent miscarriage may not require LMWH for six weeks postpartum but should receive LMWH for at least three to five days, especially if they have other risk factors.

5.5 Women without previous VTE or thrombophilia

There are few data to support recommendations for many of the individual risk factors listed in Table 1. In general, women with three or more current or persisting risk factors (other than those with a previous VTE or a thrombophilia discussed in sections 5.1–5.4) should be considered for prophylactic LMWH antenatally and for at least three to five days postpartum.

A woman with two current or persisting risk factors should be considered for prophylactic LMWH for three to five days after vaginal delivery.

Clinical judgement is required with regard to the weighting of the above risk factors. There are circumstances where one or two risk factors alone may be sufficient to justify antenatal thromboprophylaxis with LMWH, for example an extremely obese woman admitted to the antenatal ward.

The risk of VTE should be discussed with women at risk, and the reasons for individual recommendations explained.

Women with three or more persisting risk factors should be considered for thromboprophylaxis with LMWH antenatally and for three to five days postpartum.



Women should be reassessed before or during labour for risk factors for VTE. Age over 35 years and BMI greater than 30/body weight greater than 90 kg are important independent risk factors for postpartum VTE even after vaginal delivery. The combination of either of these risk factors with any other risk factor for VTE (such as pre-eclampsia or immobility) or the presence of two other persisting risk factors should lead the clinician to consider the use of LMWH for three to five days postpartum.



6. Timing and duration of thromboprophylaxis

6.1 Antepartum

As VTE during pregnancy has an equal distribution throughout gestation,⁴ if a decision is made to initiate thromboprophylaxis antenatally, this should begin as early in pregnancy as practical.⁵ Once antenatal treatment is initiated it should continue until delivery unless a specific risk factor is removed or disappears.

Women with ovarian hyperstimulation syndrome (OHSS) require thromboprophylaxis for at least the period of inpatient stay. Similarly, women with multiple risk factors for VTE and at risk of OHSS undergoing ovulation induction may also be considered for thromboprophylaxis. Advice for pregnant women travelling by air is available.³⁰

6.2 Postpartum

Postpartum thromboprophylaxis should be given as soon as possible after delivery, provided that there is no postpartum haemorrhage. Those with postpartum haemorrhage should be fitted with thromboembolic-deterrent stockings. If the woman has been given regional analgesia, LMWH should be withheld until four hours after insertion or removal of the epidural catheter (or six hours if either insertion or removal were traumatic). The first postpartum dose can be given after insertion but before removal of the epidural catheter.

As the prothrombotic changes of pregnancy do not revert completely to normal until several weeks after delivery, postpartum thromboprophylaxis is normally continued for six weeks in high-risk women.³ In practice, this will mean women learning to inject themselves if they have not already commenced heparin antenatally. However, for women at lower risk prophylaxis for three to five days is usually recommended, despite the lack of evidence in this area. Low risk includes those with two current or persisting risk factors as discussed above (Table 1) and asymptomatic thrombophilias with low thrombotic risk (heterozygous factor V Leiden and prothrombin gene variant). The risk of VTE reduces when women are mobile postpartum but does not disappear. If the woman is discharged home early, her thromboprophylaxis should be continued at home, to complete the course of three to five days. The combined oral contraceptive pill should not be prescribed during the first three months postpartum for women with other risk factors for VTE.

Just as circumstances and risk factors can change antenatally so too may they in the puerperium. Therefore, puerperal women undergoing surgery for any reason or those who develop severe infection or who choose to travel long-haul are at increased risk of VTE even though they may have been discharged from hospital following vaginal delivery several weeks before.

Antenatal thromboprophylaxis should begin as early in pregnancy as practical. Postpartum prophylaxis should begin as soon as possible after delivery (but see precautions after use of regional anaesthesia).

B

7. Agents for thromboprophylaxis

The different options for and types of treatment should be discussed with the mother.

7.1 Low molecular weight heparin

Low molecular weight heparins are the agents of choice for antenatal thromboprophylaxis. They are as effective as and safer than unfractionated heparin in pregnancy.

B

LMWHs are at least as effective as unfractionated heparin for the prevention of deep vein thrombosis in nonpregnant women undergoing surgery.³¹ Systematic reviews and retrospective studies have concluded that LMWH is a safe alternative to unfractionated heparin as an anticoagulant during pregnancy³²⁻³⁴ and from a safety perspective LMWH is preferred.

Evidence level Ia supported by levels II and III

The risk of heparin-induced thrombocytopenia is reduced with LMWH.^{35,36} Prolonged unfractionated heparin use during pregnancy may result in osteoporosis and fractures³⁵ but this risk is low with LMWH.^{32,34,37-40} Allergic skin reactions to heparin can occur³⁵ and may require a change of heparin preparation or conversion to a heparinoid (danaparoid sodium).⁴¹

See Table 2 (page 4) for suggested antenatal prophylactic and therapeutic doses of LMWH.

Experience indicates that, provided that the woman has normal renal function, monitoring of anti-Xa levels is not required when LMWH is used for thromboprophylaxis. In antithrombin deficiency, anti-Xa monitoring is critical, higher doses of LMWH may be necessary and these patients should be monitored by a haemostatic expert. Antithrombin concentrates may be required. Although the risk of heparin-induced thrombocytopenia is extremely low with LMWH³⁶ and has never been reported in pregnancy, current guidelines^{5,23} still recommend checking the platelet count one week after starting LMWH.

Where antenatal thromboprophylaxis with LMWH is given to women who are normally on long-term oral anticoagulants, usually because of previous recurrent VTE and/or a thrombophilia, higher prophylactic doses or therapeutic doses of LMWH may be appropriate (see Table 2). Whether high prophylactic doses or therapeutic doses are required is controversial and there is some evidence from nonpregnant⁴² and pregnant⁴³ data that the former may suffice.

For postpartum thromboprophylaxis, LMWH is probably the agent of choice for women who had LMWH antenatally or for those requiring only three to five days of postpartum treatment. Experience of enoxaparin in the puerperium reports no adverse effects on the baby resulting from breastfeeding.³⁵

7.2 Low-dose aspirin

Low-dose aspirin is safe in pregnancy,⁴⁴ although its use for thromboprophylaxis in this setting has never been assessed by a controlled trial. A much criticised trial suggested that low-dose aspirin, compared with placebo, reduces by 36% the risk of VTE after orthopaedic surgery, even in some women taking concomitant heparin therapy.⁴⁵ Meta-analysis of trials in surgical and medical patients also shows a significant reduction in deep vein thrombosis and pulmonary embolism with antiplatelet prophylaxis.⁴⁵ Therefore, the use of low-dose aspirin (75 mg daily) may be appropriate in situations where the risk of VTE is increased³⁰ but is not deemed high enough to warrant the use of antenatal LMWH; for example, in women with previous provoked VTE without thrombophilia.⁴⁷ Women should be advised of the lack of evidence for benefit of aspirin use for thromboprophylaxis in pregnancy.

7.3 Warfarin

Warfarin should be avoided if possible during pregnancy,⁵ especially between 6 and 12 weeks of gestation, because it is associated with an up to 5% risk of teratogenesis and increases the risk of miscarriage, fetal and maternal haemorrhage, neurological problems in the baby and stillbirth.⁴⁸

Warfarin is safe after delivery and for breastfeeding, although it requires close monitoring, frequent visits to an anticoagulant clinic and carries an increased risk of postpartum haemorrhage and perineal haematoma compared with LMWH. It is not appropriate for women requiring only three to five days of postpartum prophylaxis.

If the woman chooses to commence warfarin postpartum, this can usually be initiated on the second or third postnatal day. LMWH should be continued until the international normalised ratio is greater than 2.0. The dosage regimens are the same as for women converting to warfarin postpartum following an acute VTE in pregnancy.²

Warfarin should usually be avoided during pregnancy. It is safe after delivery and during breastfeeding.

B

7.4 Dextran

Dextran should not be used primarily because of the risk of anaphylaxis, which has killed fetuses by causing massive histamine release and uterine hypertonus.

7.5 Graduated elastic compression stockings

Graduated elastic compression stockings may be used antenatally. There are no trials to support such practice but the British Society for Haematology guidelines²³ give a grade C recommendation (evidence level IV) that all women with previous VTE or a thrombophilia should be encouraged to wear class-II graduated elastic compression below knee stockings throughout their pregnancy and for 6–12 weeks after delivery. Class-I thromboelastic stockings are appropriate for hospital inpatients at increased risk of VTE and may be combined with LMWH. Their use is also recommended for pregnant women travelling by air.³⁰

8. Care during labour and delivery for women on thromboprophylaxis

Once the woman is in labour or thinks she is in labour, she should be advised not to inject any further heparin. She should be reassessed on admission to hospital and further doses should be prescribed by medical staff.



The pregnancy-associated prothrombotic changes in the coagulation system are maximal immediately following delivery. Therefore, it is desirable to continue LMWH during labour or delivery in women receiving antenatal thromboprophylaxis with LMWH. For women receiving high prophylactic or therapeutic doses of LMWH, the dose of heparin should be withheld if the woman goes into labour or reduced to its thromboprophylactic dose on the day before induction of labour or elective caesarean section and continued in this dose during labour. If the woman is of normal weight, the dose for unfractionated heparin should be 5000 units 12 hourly. For LMWH preparations, a once-daily regimen should be adopted using the following doses: enoxaparin 40 mg, dalteparin 5000 iu, tinzaparin 50 units/kg.^{49,50}

Epidural anaesthesia can be sited only after discussion with a senior anaesthetist, in keeping with local anaesthetic protocols.² It is important to discuss the implication of treatment with heparin or LMWH for epidural or spinal anaesthesia with the woman before labour or caesarean section. To minimise the risk of epidural haematoma, regional techniques should not be used until at least 12 hours after the previous prophylactic dose of LMWH. When a woman presents while on a therapeutic regimen of LMWH, regional techniques should not be employed for at least 24 hours after the last dose of LMWH.⁵¹ LMWH should not be given for at least four hours after the epidural catheter has been inserted or removed and the cannula should not be removed within 10–12 hours of the most recent injection.⁵²

For delivery by elective caesarean section, the woman should receive a thromboprophylactic dose of LMWH on the day before delivery. On the day of delivery, the morning dose should be omitted and the operation performed that morning. The thromboprophylactic dose of LMWH should be given by three hours postoperatively (or four hours after insertion or removal of the epidural catheter, if appropriate). There is an

increased risk of around 2% of wound haematoma following caesarean section with both unfractionated heparin and LMWH.

Women at high risk of haemorrhage with risk factors including major antepartum haemorrhage, coagulopathy, progressive wound haematoma, suspected intraabdominal bleeding and postpartum haemorrhage may be more conveniently managed with unfractionated heparin. Unfractionated heparin has a shorter half-life than LMWH and there is more experience in the use of protamine sulphate to reverse its activity. If a woman develops a haemorrhagic condition while taking LMWH, the treatment should be stopped and expert haematological advice sought.² It should be remembered that excess blood loss and blood transfusion are risk factors for VTE, so thromboprophylaxis should be commenced or reinstated as soon as the immediate risk of haemorrhage is reduced.

9. Topics suitable for audit

- Proportion of women with previous venous thromboembolism who undergo screening for thrombophilia
- Proportion of women with previous venous thromboembolism who receive six weeks postnatal LMWH

Key recommendations

All women should undergo an assessment of risk factors for VTE in early pregnancy or before pregnancy. This assessment should be repeated if the woman is admitted to hospital or develops other intercurrent problems.

C

Women with previous VTE should be screened for inherited and acquired thrombophilia, ideally before pregnancy.

B

Regardless of their risk of VTE, immobilisation of women during pregnancy, labour and the puerperium should be minimised and dehydration should be avoided.

✓

Women with previous VTE should be offered postpartum thromboprophylaxis with LMWH. It may be reasonable not to use antenatal thromboprophylaxis with heparin in women with a single previous VTE associated with a temporary risk factor that has now resolved.

C

Women with previous recurrent VTE or a previous VTE and a family history of VTE in a first-degree relative should be offered thromboprophylaxis with LMWH antenatally, and for at least six weeks postpartum.

C

Women with previous VTE and thrombophilia should be offered thromboprophylaxis with LMWH antenatally and for at least six weeks postpartum.

B

Women with asymptomatic inherited or acquired thrombophilia may qualify for antenatal or postnatal thromboprophylaxis, depending on the specific thrombophilia and the presence of other risk factors.

C

Women with three or more persisting risk factors should be considered for thromboprophylaxis with LMWH antenatally and for three to five days postpartum.

✓

Women should be reassessed before or during labour for risk factors for VTE. Age over 35 years and BMI greater than 30/body weight greater than 90 kg are important independent risk factors for postpartum VTE even after vaginal delivery. The combination of either of these risk factors with any other risk factor for VTE (such as pre-eclampsia or immobility) or the presence of two other persisting risk factors should lead the clinician to consider the use of LMWH for three to five days postpartum.

✓

Antenatal thromboprophylaxis should begin as early in pregnancy as practical. Postpartum prophylaxis should begin as soon as possible after delivery (but see precautions after use of regional anaesthesia). B

LMWHs are the agents of choice for antenatal thromboprophylaxis. They are as effective as and safer than unfractionated heparin in pregnancy. B

Warfarin should usually be avoided during pregnancy. It is safe after delivery and during breastfeeding. B

Once the woman is in labour or thinks she is in labour, she should be advised not to inject any further heparin. She should be reassessed on admission to hospital and further doses should be prescribed by medical staff.

| Risk | Previous VTE and/or thrombophilia status | Prophylaxis |
|-----------|---|---|
| Very high | Previous VTE (\pm thrombophilia) on long-term warfarin | Antenatal high prophylactic or therapeutic dose LMWH and at least six weeks of postnatal warfarin |
| High | Previous recurrent VTE not on long-term warfarin Previous VTE + thrombophilia Previous VTE + family history of VTE Asymptomatic thrombophilia (antithrombin deficiency, combined defects, homozygous factor V Leiden or prothrombin gene defect) | Antenatal and six weeks postnatal prophylactic LMWH |
| Moderate | Single previous provoked VTE without thrombophilia, family history or other risk factors Asymptomatic thrombophilia (except antithrombin deficiency, combined defects, homozygous FVL or prothrombin gene defect) | Six weeks of postnatal prophylactic LMWH \pm antenatal low-dose aspirin |

^a These women require joint specialist management by obstetricians and experts in haemostasis and pregnancy

References

1. Royal College of Obstetricians and Gynaecologists. *Report of the RCOG Working Party on Prophylaxis Against Thromboembolism in Gynaecology and Obstetrics*. London: RCOG Press; 1995.
2. Royal College of Obstetricians and Gynaecologists. *Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management*. Guideline No. 28. London: RCOG Press; 2001.
3. Drife J, Lewis G, editors. *Why Mothers Die 1997-1999: Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom*. London: RCOG Press; 2001.
4. Ray JG, Chan WA. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. *Obstet Gynecol Surv* 1999; 54: 265-71.
5. Scottish Intercollegiate Guidelines Network. Pregnancy and the puerperium. In: *Antithrombotic Therapy*. SIGN Publication No. 36. Edinburgh: SIGN; 1999.
6. Ginsberg JS, Greer IA, Hirsh J. Sixth ACCP Consensus Conference on Antithrombotic therapy. Use of anti-thrombotic agents during pregnancy. *Chest* 2001; 119: 122s-31s.
7. Hague WM, North RA, Gallus AS, Walters BN, Orlikowski C, Burrows RE *et al*. Anticoagulation in pregnancy and the puerperium. A Working Group on behalf of the Obstetric Medicine Group of Australasia. *Med J Aust* 2001; 175: 258-63.
8. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period *Cochrane Database Syst Rev* 2002; (2).
9. McColl M, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, *et al*. Risk factors for pregnancy associated venous thromboembolism. *Thromb Haemost* 1997; 78: 1183-8.
10. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RDT. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. *BJOG* 2001; 108: 56-60.
11. Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, *et al*. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. *Blood* 2002; 100: 1060-2.
12. Brill-Edwards P, Ginsberg JS, for the Recurrence Of Clot In This Pregnancy (ROCIT) Study Group. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. *N Engl J Med* 2000; 343: 1439-44.
13. Gerhardt A, Scharf RE, Beckman MW, Struve S, Bender HG, Pillny M, *et al*. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. *N Engl J Med* 2000; 342: 374-80.
14. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. *N Engl J Med* 2000; 342: 424-5.
15. Martinelli I, de Stefano V, Taiolo E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and the puerperium. *Thromb Haemost* 2002; 87: 791-5.
16. McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. *BJOG* 2000; 107: 565-9.
17. McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. *Br J Obstet Gynaecol* 1999; 75: 387-8.
18. McLintock C, North RA, Dekker G. Inherited thrombophilias: associated venous thromboembolism and obstetric complications. *Curr Probl Obstet Gynecol Fertil* 2001; 24: 109-52.
19. Conard J, Horellou MH, van Dreden P, Le Compte T, Samama M. Thrombosis in pregnancy and congenital deficiencies in AT III, protein C or protein S: study of 78 women. *Thromb Haemost* 1990; 63: 319-20.
20. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, *et al*. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. *Arch Intern Med* 1996; 125: 955-60.
21. Martinelli I, Legnani C, Bucciarelli P, Grandone E, de Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. *Thromb Haemost* 2001; 86: 800-3.
22. Middeldorp S, Libourel EJ, Hamulyak K, van der Meer J, Buller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. *Br J Haematol* 2001; 113: 553-5.
23. Walker ID, Greaves M, Preston FE. British Society for Haematology Guideline. Investigation and management of heritable thrombophilia. *Br J Haematol* 2001; 114: 512-28.
24. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC *et al*. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop. *Arthritis Rheum* 1999; 42: 1309-11.
25. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332: 993-7.
26. Shehata HA, Nelson-Piercy C, Khamashta MA. Management of pregnancy in antiphospholipid syndrome. In Khamashta MA (ed) *Antiphospholipid (Hughes) syndrome*. *Rheum Dis Clin North Am* 2001; 27: 643-59.
27. Stone S, Langford K, Nelson-Piercy C, Khamashta M, Bewley S, Hunt BJ. Antiphospholipid antibodies do not a syndrome make. *Lupus* 2002; 11: 130-3.
28. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddel HS, McDougal J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial. *Am J Obstet Gynecol* 2000; 183: 1008-12.
29. Cowchock S, Reece A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? *Am J Obstet Gynecol* 1997; 176: 1099-100.
30. Royal College of Obstetricians and Gynaecologists. *Advice on Preventing Deep Vein Thrombosis for Pregnant Women Travelling by Air*. Scientific Advisory Committee Opinion Paper 1. London: RCOG Press; 2001.
31. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke P, *et al*. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. *Lancet* 1992; 340: 152-6.
32. Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, *et al*. Safety of low-molecular-weight heparin in pregnancy: a systematic review. *Thromb Haemost* 1999; 81: 668-72.
33. Ensom MHH, Stephenson MD. Low molecular weight heparins in pregnancy. *Pharmacotherapy* 1999; 19: 1013-25.
34. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, *et al*. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. *Br J Obstet Gynaecol* 2001; 108: 1134-40.
35. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. *Baillière's Clin Obstet Gynaecol* 1997; 11: 489-509.

36. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, *et al*. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. *N Engl J Med* 1995; 332: 1330-5.
37. Schulman S, Hellgren-Wangdahl M. Pregnancy, heparin and osteoporosis. *Thromb Haemost* 2002; 87: 180-1.
38. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. *Thromb Haemost* 2002; 87: 182-6.
39. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. *Eur J Obstet Gynecol Reprod Biol* 1996; 65: 171-4.
40. Monreal M. Long-term treatment of venous thromboembolism with low-molecular weight heparin. *Curr Opin Pulm Med* 2000; 6: 326-9.
41. Taylor AA. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. *Br J Obstet Gynaecol* 2001; 108: 1011-2.
42. CLOT investigators. Low molecular weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT study). *N Engl J Med* 2003; 349: 109-11.
43. Hunt HJ, Gattens M, Khamashta MA, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate dose LMWH in pregnancies with a previous arterial or venous thrombotic event. *Blood Coag Fibrinolysis* 2003; 14: 1-5.
44. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. *Lancet* 1994; 343: 619-29.
45. Pulmonary embolism prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep venous thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet* 2000; 355: 1295-302.
46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *BMJ* 1994; 308: 235-46.
47. Tan J, De Swiet M. Use of aspirin for obstetric thromboprophylaxis in low risk women. *J Obstet Gynaecol* 1998; 18 (Suppl 1): 546-7.
48. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. *Arch Intern Med* 2000; 160: 191-6.
49. Dahlman TC, Hellgren MS, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. *Am J Obstet Gynecol* 1989; 161: 420-5.
50. Togli MR, Weg JG. Venous thromboembolism during pregnancy. *N Engl J Med* 1996; 335: 108-14.
51. Checketts MR, Wildsmith JA. Central nerve block and thromboprophylaxis: is there a problem? *Br J Anaesth* 1999; 82: 164-7.
52. Horlocker TT, Wedel DJ. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic. *Anesth Analg* 1998; 86: 1153-6.

APPENDIX

Clinical guidelines are: 'systematically developed statements which assist clinicians and patients in making decisions about appropriate treatment for specific conditions'. Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No. 1: *Guidance for the Development of RCOG Green-top Guidelines* (available on the RCOG website at www.rcog.org.uk/clingov1). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.

The evidence used in this guideline was graded using the scheme below and the recommendations formulated in a similar fashion with a standardised grading scheme.

| Classification of evidence levels | | Grades of recommendations | |
|-----------------------------------|---|-------------------------------------|--|
| Ia | Evidence obtained from meta-analysis of randomised controlled trials. | A | Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib) |
| Ib | Evidence obtained from at least one randomised controlled trial. | | |
| IIa | Evidence obtained from at least one well-designed controlled study without randomisation. | B | Requires the availability of well controlled clinical studies but no randomised clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) |
| IIb | Evidence obtained from at least one other type of well-designed quasi-experimental study. | | |
| III | Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies. | C | Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV) |
| IV | Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities. | <input checked="" type="checkbox"/> | Good practice point Recommended best practice based on the clinical experience of the guideline development group. |

This guideline was produced on behalf of the Royal College of Obstetricians and Gynaecologists by:

Dr C Nelson-Piercy FRCP, St Thomas' Hospital, London

and peer reviewed by:

Dr S Bewley FRCOG, London; Professor M De Swiet FRCOG, London; Professor IA Greer FRCOG, Glasgow; Dr B J Hunt, haematologist, Guys and St Thomas' Trust, London; Dr M Oakland, Laboratory Manager, Department of Haematology, Birmingham Women's Hospital; RCOG Consumers Forum; Professor FJM Reynolds FRCOG, London; Mr PJ Thompson MRCOG, London; Dr J Voke, haematologist, Queen Elizabeth II Hospital, Welwyn Garden City.

The final version is the responsibility of the Guidelines and Audit Committee of the RCOG.

Valid until January 2006
unless otherwise indicated